Post-earnings recap
Reported
Wed, Aug 5, 2026
EPS actual
$2.58
EPS est.
$1.87
EPS surprise
+37.75%
1-day move
-5.08%
CVS Health's earnings report shows a significant earnings per share beat, indicating better-than-expected profitability. However, the stock fell by over 5%, suggesting that investors may have had concerns about other aspects of the business, such as revenue performance or future outlook, which were not detailed in the report.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.58 | $1.85 | +37.75% |
| Revenue | N/A | $100.1B | N/A |
No transcript is on record, and the analysis is based solely on numerical results.
CVS Health Corporation is a major player in the health care sector, providing a range of services including pharmacy benefits management and retail pharmacy services. With a market cap of $121 billion, CVS is positioned at the intersection of health care and consumer services, making it a significant entity in the ongoing discussions about health care accessibility and affordability.
Last quarter
In Q1 2026, CVS reported an EPS of $2.57, surpassing estimates by 16.39%. The stock reacted positively, increasing by 7.65% the following day.
Management promises and guidance
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+21.45%
Avg 1-day reaction
+3.82%
Analysts expect CVS to report strong earnings, driven by consistent demand in health care services. The consensus EPS of $1.85 reflects optimism about the company's ability to maintain profitability.
Bull case
If CVS exceeds the EPS estimate, it could signal strong operational efficiency and robust demand for its services, potentially leading to a positive stock reaction.
Bear case
Conversely, if CVS falls short of expectations, it may raise concerns about its market position and ability to manage costs, leading to a negative impact on the stock.
Key metrics to watch
EPS
$1.85Earnings per share is a key indicator of profitability and will help assess how well CVS is managing costs and revenues.
Revenue
$100.1BTotal revenue gives insight into the overall business performance and growth, especially in a competitive health care landscape.
The print will turn on these.
Q1
Will CVS's EPS exceed the consensus estimate of $1.85?
A beat on EPS could reinforce investor confidence in CVS's operational efficiency and growth strategy.
Q2
What guidance will CVS provide regarding revenue growth in its pharmacy services?
Insights into revenue growth will be crucial for understanding CVS's market position and future prospects in a competitive landscape.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±12.7%
Why consensus could be wrong
The Street may underestimate CVS's ability to leverage its pharmacy services for growth, especially in light of recent health care trends.
Supporting evidence
CVS has consistently beaten EPS estimates, indicating strong operational management.
The options market is pricing a larger move than historical averages, suggesting heightened expectations.
Recent trends in health care spending may favor CVS's diversified service offerings.
Key risk
If CVS's revenue growth in pharmacy services falls below $98 billion, it could challenge the current bullish consensus.
Pre-commit to what would confirm each case.
This quarter's performance will be closely watched as it reflects CVS's ability to navigate a challenging health care environment and meet investor expectations.
Bull confirmed if
An EPS of $1.90 or higher would confirm strong operational performance and growth.
Bear confirmed if
An EPS below $1.75 would raise concerns about CVS's ability to manage costs and maintain profitability.
What the market is pricing for the move.
Implied Move
±7.03%
Historical Avg
±5.7%
The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings announcement.
Options are pricing ±7.0% while CVS has averaged ±5.7% over the last 8 prints — setup is pricing rich.
ATM IV
0.3%
30d HV
35.7%
Smart-money positioning from the most recent 13F filings.
Institutional
90.83%
of float
Insider
0.06%
of float
Holders
2,660
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
123,223,409 sh · $10.8B
9.63%
-2.1%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If CVS beats expectations, history suggests a potential stock increase of around 4.06%, confirming strong operational performance.
In line / cautious
An in-line report may lead to a muted reaction, as investors await further commentary on future growth prospects.
Miss
A miss could result in a decline, with history suggesting a potential drop based on past performance.
The lines on the call that would change the story.
Vanguard Capital Management LLC
83,315,369 sh · $7.3B
6.51%
0.8%
Capital World Investors
74,951,955 sh · $6.6B
5.86%
-3.0%
State Street Corporation
60,283,408 sh · $5.3B
4.71%
1.6%
Dodge & Cox Inc.
50,012,765 sh · $4.4B
3.91%
-3.4%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.